StockData
LivaNova PLC logo

LivaNova PLC (LIVN) stock

LIVNNasdaqElectromedical & Electrotherapeutic ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 13/3032% above fair value
$91.92−0.52 (-0.56%)

Close on Nov 17, 2026Market cap $5.06BP/E 27.1Yield –

LivaNova PLC grew revenue 12.4% to $1.47B over the twelve months to Jun 30, 2026. Operating income rose 6.9% to $187.55M, moving the operating margin from 13.4% to 12.7%. Free cash flow was $148.31M, down 8.5% from a year earlier. At the latest close the market valued the company at $5.06B, 27.1 times its earnings.

Revenue
$1.47B
+12.4% vs. a year earlier
Operating income
$187.55M
+6.9% vs. a year earlier
Free cash flow
$148.31M
-8.5% vs. a year earlier
EPS, diluted
$3.39
TTM Q2 2026

Key statistics

Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026

Valuation

Market cap
$5.06B
P/E ratio
27.1
Price to sales
3.44
Price to book
3.82
Dividend yield
–
Free cash flow yield
2.93%

Fundamentals

Revenue
$1.47B
Net income
$188.55M
EPS, diluted
$3.39
Free cash flow
$148.31M
Book value per share
$23.55
Diluted shares
56M

Trading

Next earnings
Feb 24, 2027 (estimated, before the open)
Previous close
$92.44
Open
$92.72
Day's range
$91.63 – $93.64
Volume
573,618
Average volume (20 days)
782,874
52-week range
$52.37 – $99.38
RSI (14 days)
65.6
Volatility (1 year)
39.1%
Relative volume
0.85×

Market cap history

Month-end market cap since 2013, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Nov 17, 2026. The S&P 500 is measured by the SPY fund.

PeriodLIVNS&P 500DifferenceLIVN per yearS&P 500 per year
1 month+18.5%-4.0%+22.5 pts
3 months+12.8%-5.0%+17.8 pts
Year to date+49.4%+8.2%+41.1 pts
1 year+71.4%+11.2%+60.1 pts
3 years+96.5%+68.5%+28.1 pts+25.3%+19.0%
5 years+6.9%+67.3%−60.3 pts+1.3%+10.8%
10 years+112.6%+291.6%−179.1 pts+7.8%+14.6%

Thirteen years at a glance

Fiscal years 2012 to 2025 and trailing twelve months, USD

Revenue

$1.47B+12.4% YoY

Gross profit

$1.00B+12.5% YoY

Operating income

$187.55M+6.9% YoY

Net income

$188.55M

EPS, diluted

$3.39

Free cash flow

$148.31M-8.5% YoY
Reported periodTrailing twelve months

Press releases

Releases LivaNova filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About LivaNova

Electromedical & Electrotherapeutic Apparatus

LivaNova PLC is a medical technology company that designs, develops, manufactures, and markets medical devices, therapies, and related services. The company operates through two primary segments: Cardiopulmonary and Neuromodulation. Its Cardiopulmonary portfolio includes heart-lung machines, oxygenators, autotransfusion systems, cannulae, and perfusion tubing systems utilized during cardiac surgeries. The Neuromodulation business offers vagus nerve stimulation therapy systems for treating drug-resistant epilepsy and difficult-to-treat depression, along with an implantable neurostimulation system under development for obstructive sleep apnea. LivaNova provides its products to hospitals, medical institutions, and healthcare professionals such as perfusionists, neurologists, and neurosurgeons.

Company profile, executives and history

LivaNova stock: common questions

What is LivaNova's stock price?

LIVN closed at $91.92 on Nov 17, 2026, down 0.56% on the day. Over the past 52 weeks it traded between $52.37 and $99.38.

What is LivaNova's market cap?

LivaNova was worth $5.06B at the close on Nov 17, 2026: the share price times the diluted shares outstanding.

What is LIVN's P/E ratio?

LIVN trades at 27.1 times earnings, based on diluted earnings per share of $3.39 over the twelve months to Jun 30, 2026.

How much revenue does LivaNova make?

LivaNova reported revenue of $1.47B for the twelve months to Jun 30, 2026, up 12.4% from a year earlier.

Does LivaNova pay a dividend?

No. LivaNova has not paid a cash dividend over the last twelve months.

When does LivaNova report earnings next?

LivaNova is expected to report Q4 FY2026 results on Feb 24, 2027, before the open. The date is estimated from its past reporting pattern until the company confirms it.

How has LIVN stock performed over the past year?

Including dividends, LIVN returned +71.4% over the past year, against +11.2% for the S&P 500.

How many LIVN shares are sold short?

6M shares were sold short at the latest FINRA report, 11.60% of the float, or 12.4 days of average trading volume.

Who are LivaNova's competitors?

Companies most similar to LivaNova by business, industry and size include CNMD, ITGR, IART, MMSI, TMDX.

See a number that looks wrong?